

mechanistic understanding of a drug action, the preclinical database is a valuable tool to support an efficient and informative clinical drug development which leads to a successful regulatory approval.

ACKNOWLEDGEMENTS

I would like to thank Prof. Carl Peck, MD, PhD (hon.), Director, Center for Drug Development Science, Georgetown University Medical Center, for his encouragement and mentoring. I borrowed many of his ideas on rational drug development in this chapter. In fact, the enthusiasm for efficient drug development based on clinical pharmacology, transferred to me from Prof. Peck, enabled me to write this chapter. Dr. Charles Grudzinskas also helped me form perspectives on the current drug development practices. I was able to systematically study many NDA cases introduced in this chapter with his help and guidance. I also want to thank Dr. Stacey Tannenbaum for her edits and valuable comments on the contents.

REFERENCES

1. Groneberg DA, Grosse-Siestrup C, Fischer A. *In vitro* models to study hepatotoxicity. *Toxicol Pathol* 2002; 30(3):394–399.
2. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline (S7A). Safety Pharmacology Studies for Human Pharmaceuticals. 2000.
3. Gerlach M, Foley P, Riederer P. The relevance of preclinical studies for the treatment of Parkinson's disease. *J Neurol* 2003; 250(suppl 1):I31–I34.
4. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. *Pharm Res* 2000; 17(11):1335–1344.
5. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. *Clin Pharmacol Ther* 1992; 51(4):465–473.
6. Serabian MA, Pilaro AM. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. *Toxicol Pathol* 1999; 27(1):27–31.
7. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline (S6). Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. 1997.
8. Dangoumau JA. From discovery to market availability. In: Wermuth CG, ed. *The Practice of Medicinal Chemistry*. London: Academic Press, 1996:847–862.
9. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001; 69(3):89–95.